HBIO logo

Harvard Bioscience, Inc. Stock Price

NasdaqCM:HBIO Community·US$18.7m Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 7 Fair Values set on narratives written by author

HBIO Share Price Performance

US$0.42
-2.07 (-83.15%)
79.0% undervalued intrinsic discount
US$2.00
Fair Value
US$0.42
-2.07 (-83.15%)
79.0% undervalued intrinsic discount
US$2.00
Fair Value
Price US$0.42
AnalystConsensusTarget US$2.00

HBIO Community Narratives

AnalystConsensusTarget·
Fair Value US$2 77.8% undervalued intrinsic discount

Demographic Shifts And NIH Funding Will Unlock Biomedical Potential

0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative

Recent HBIO News & Updates

Harvard Bioscience, Inc. (NASDAQ:HBIO) Just Reported, And Analysts Assigned A US$3.00 Price Target

Aug 14
Harvard Bioscience, Inc. (NASDAQ:HBIO) Just Reported, And Analysts Assigned A US$3.00 Price Target

Does Harvard Bioscience (NASDAQ:HBIO) Have A Healthy Balance Sheet?

Jul 23
Does Harvard Bioscience (NASDAQ:HBIO) Have A Healthy Balance Sheet?

Harvard Bioscience, Inc. Key Details

US$88.8m

Revenue

US$38.2m

Cost of Revenue

US$50.5m

Gross Profit

US$107.9m

Other Expenses

-US$57.4m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-1.29
Gross Margin
56.94%
Net Profit Margin
-64.68%
Debt/Equity Ratio
221.9%

Harvard Bioscience, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Fair value with mediocre balance sheet.

3 Risks
1 Reward

About HBIO

Founded
1901
Employees
343
CEO
John Duke
WebsiteView website
www.harvardbioscience.com

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States, Germany, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

U.S. Market Performance

  • 7 Days: -2.7%
  • 3 Months: 5.1%
  • 1 Year: 13.4%
  • Year to Date: 11.7%
Over the last 7 days, the market has dropped 2.7%, driven by a loss of 2.5% in the Information Technology sector. As for the longer term, the market has actually risen by 13% in the last year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›